Among 3 analysts covering Turkcell (NYSE:TKC), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Turkcell had 4 analyst reports since September 3, 2015 according to SRatingsIntel. JP Morgan downgraded the stock to “Neutral” rating in Wednesday, April 6 report. The stock of Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE:TKC) has “Buy” rating given on Thursday, January 5 by Deutsche Bank. The firm earned “Overweight” rating on Thursday, September 17 by JP Morgan. The stock of Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE:TKC) earned “Neutral” rating by Bank of America on Thursday, September 3. See Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE:TKC) latest ratings:
05/01/2017 Broker: Deutsche Bank Old Rating: Hold New Rating: Buy Upgrade
The stock of Interpace Diagnostics Group Inc (NASDAQ:IDXG) gapped up by $0.07 today and has $2.94 target or 4.00% above today’s $2.83 share price. The 8 months technical chart setup indicates low risk for the $15.32 million company. The gap was reported on Mar, 22 by Barchart.com. If the $2.94 price target is reached, the company will be worth $612,800 more. About 9.42 million shares traded or 2378.66% up from the average. Interpace Diagnostics Group Inc (NASDAQ:IDXG) has declined 9.26% since August 15, 2016 and is downtrending. It has underperformed by 16.28% the S&P500.
Analysts await Interpace Diagnostics Group Inc (NASDAQ:IDXG) to report earnings on March, 29.
Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The company has market cap of $15.32 million. The Firm operates through molecular diagnostics segment. It currently has negative earnings. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay.
Turkcell Iletisim Hizmetleri AS is engaged in establishing and operating a Global System for Mobile Communications network in Turkey and regional states. The company has market cap of $7.37 billion.
About 244,448 shares traded. Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE:TKC) has declined 2.42% since August 15, 2016 and is downtrending. It has underperformed by 9.44% the S&P500.
